Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Reiki Nishimura

Showing results (11-20 of 80) with videos related to

Pageof 8
Sort By:
Experimental and Therapeutic Medicine|September 21, 2012
Ki-67 as a prognostic marker according to breast cancer subtype and a predictor of recurrence time in primary breast cancerReiki Nishimura, Tomofumi Osako, Yasuhiro Okumura, et al.
Anticancer Research|May 1, 2007
Dosage of capecitabine and cyclophosphamide combination therapy in patients with metastatic breast cancerShinji Ohno, Shoshu Mitsuyama, Kazuo Tamura, et al.
Oncology Letters|August 7, 2012
Shift in cytotoxic target from estrogen receptor-positive to estrogen receptor-negative breast cancer cells by trastuzumab in combination with taxane-based chemotherapyMitsuhiro Hayashi, Kazuharu Kai, Yasuhiro Okumura, et al.
Oncology Letters|June 28, 2022
An evaluation of lymphovascular invasion in relation to biology and prognosis according to subtypes in invasive breast cancerReiki Nishimura, Tomofumi Osako, Yasuhiro Okumura, et al.
Surgery Today|January 13, 2012
Mucocele-like tumor associated with ductal carcinoma in situ diagnosed as mucinous carcinoma by fine-needle aspiration cytology: report of a caseShoichi Kikuchi, Reiki Nishimura, Tomofumi Osako, et al.
Journal of Clinical Medicine|May 14, 2022
Triple Negative Breast Cancer: An Analysis of the Subtypes and the Effects of Menopausal Status on Invasive Breast CancerReiki Nishimura, Tomofumi Osako, Yasuhiro Okumura, et al.
International Journal of Clinical Oncology|May 11, 2011
Time to first tumor progression as a predictor of efficacy of continued treatment with trastuzumab beyond progression in human epidermal growth factor receptor 2-positive metastatic breast cancerMitsuhiro Hayashi, Yasuhiro Okumura, Tomofumi Osako, et al.
Anticancer Research|September 12, 2013
Definition of p53 overexpression and its association with the clinicopathological features in luminal/HER2-negative breast cancerShoichi Kikuchi, Reiki Nishimura, Tomofumi Osako, et al.
Internal Medicine (Tokyo, Japan)|October 20, 2024
Delayed Trastuzumab-induced Cardiotoxicity Leading to Severe Left Ventricular DysfunctionIkuo Misumi, Reiki Nishimura, Shota Nakamura, et al.
Breast Cancer (Tokyo, Japan)|May 9, 2003
Higher plasma vascular endothelial growth factor levels correlate with menopause, overexpression of p53, and recurrence of breast cancerReiki Nishimura, Kazuharu Nagao, Haruhiko Miyayama, et al.
Pageof 8

Showing results (11-20 of 80) with videos related to

Sort By:
Pageof 8
Experimental and Therapeutic Medicine|September 21, 2012
Ki-67 as a prognostic marker according to breast cancer subtype and a predictor of recurrence time in primary breast cancerReiki Nishimura, Tomofumi Osako, Yasuhiro Okumura, et al.
Anticancer Research|May 1, 2007
Dosage of capecitabine and cyclophosphamide combination therapy in patients with metastatic breast cancerShinji Ohno, Shoshu Mitsuyama, Kazuo Tamura, et al.
Oncology Letters|August 7, 2012
Shift in cytotoxic target from estrogen receptor-positive to estrogen receptor-negative breast cancer cells by trastuzumab in combination with taxane-based chemotherapyMitsuhiro Hayashi, Kazuharu Kai, Yasuhiro Okumura, et al.
Oncology Letters|June 28, 2022
An evaluation of lymphovascular invasion in relation to biology and prognosis according to subtypes in invasive breast cancerReiki Nishimura, Tomofumi Osako, Yasuhiro Okumura, et al.
Surgery Today|January 13, 2012
Mucocele-like tumor associated with ductal carcinoma in situ diagnosed as mucinous carcinoma by fine-needle aspiration cytology: report of a caseShoichi Kikuchi, Reiki Nishimura, Tomofumi Osako, et al.
Journal of Clinical Medicine|May 14, 2022
Triple Negative Breast Cancer: An Analysis of the Subtypes and the Effects of Menopausal Status on Invasive Breast CancerReiki Nishimura, Tomofumi Osako, Yasuhiro Okumura, et al.
International Journal of Clinical Oncology|May 11, 2011
Time to first tumor progression as a predictor of efficacy of continued treatment with trastuzumab beyond progression in human epidermal growth factor receptor 2-positive metastatic breast cancerMitsuhiro Hayashi, Yasuhiro Okumura, Tomofumi Osako, et al.
Anticancer Research|September 12, 2013
Definition of p53 overexpression and its association with the clinicopathological features in luminal/HER2-negative breast cancerShoichi Kikuchi, Reiki Nishimura, Tomofumi Osako, et al.
Internal Medicine (Tokyo, Japan)|October 20, 2024
Delayed Trastuzumab-induced Cardiotoxicity Leading to Severe Left Ventricular DysfunctionIkuo Misumi, Reiki Nishimura, Shota Nakamura, et al.
Breast Cancer (Tokyo, Japan)|May 9, 2003
Higher plasma vascular endothelial growth factor levels correlate with menopause, overexpression of p53, and recurrence of breast cancerReiki Nishimura, Kazuharu Nagao, Haruhiko Miyayama, et al.
Pageof 8